Categories Consumer, Earnings, Retail

After rating upgrade, Kellogg stock poised to gain further

Shares of convenience food provider Kellogg Company (NYSE: K) made strong gains on Friday and traded close to their recent peak, after Goldman Sachs issued a bullish statement on the company.

Impressed by its positive momentum, the brokerage upgraded the stock to buy from neutral and raised the target price to $72. The shares closed the session up 2%. According to Goldman, Kellogg’s profit margins will expand significantly on the back of solid organic sales growth.

Related: Beyond Meat stock gets a boost after rating upgrade

The analyst also referred to Kellogg as the ‘the most compelling value left in snacks,’ citing the growth prospects of the business. Going by the current trend, it is likely that other brokerages would follow suit in the coming days and upgrade their ratings on the stock.

Kellogg Q2 profit drops but beats estimates

Kellogg got a major boost after its stronger-than-expected second-quarter results triggered a stock rally a few weeks ago. Though sales increased 3% to $3.5 billion, the bottom line slipped due to charges related to the ongoing restructuring program and high input costs. Earnings dropped 13% to $0.99 per share.

The recent divestiture of under-performing categories like cookies, fruit snacks, pie crusts, and ice cream cones is seen as an effective strategy that would help the company streamline its business. Betting on the growing demand for plant-based fast-food, Kellogg recently introduced ‘Incogmeato’, its vegan-meat range of burgers, tenders and chicken nuggets.

Also read: Kellogg Q2 2019 Earnings Conference Call Transcript

The rating upgrade comes at a time when the majority of analysts covering Kellogg recommend hold and maintain relatively low price targets. Last month, the stock climbed to the highest level in nearly a year. It has gained 13% since the beginning of the year.

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top